Meta description: Spiro Medical closes a $67M Series A funding round to advance its pulmonary neuromodulation system and pursue US regulatory approval.
Spiro Medical, headquartered in Irvine, California, has completed a $67 million Series A funding round. The medtech company is focused on developing a pulmonary neuromodulation system aimed at treating severe asthma, chronic cough, and COPD. This substantial capital injection positions the company to accelerate product development and navigate the clinical and regulatory pathways in the United States. The announcement is of interest to medtech investors, startup founders, and healthcare industry strategists tracking innovation in respiratory treatments.
Who invested in this round?
The $67 million Series A was led by Andera Partners from Paris, Omega Funds with presence in Geneva and Boston, and Sherpa Healthcare Partners based in the Cayman Islands. Other participants include HSG from Hong Kong, Supernova Invest in Paris, Northern Light Venture Capital from Menlo Park, California, and Hero Inc. Ltd UK, part of India’s Hero Enterprise group.
This diverse investor syndicate brings international reach and deep sector expertise. The backing includes venture firms with track records in healthcare innovation, suggesting strong confidence in Spiro Medical’s technical and commercial potential.
What does this mean for growth?
According to the funding details, proceeds will be allocated toward developing new systems and conducting the required clinical work for regulatory clearance in the United States. The company’s pulmonary neuromodulation system is drug-free and uses mild electrical impulses to manage respiratory symptoms.
For a medical device startup, early-stage funding of this scale offers room to expand technical teams, strengthen manufacturing capabilities, and advance trials. Regulatory approval is a key milestone that could open significant market opportunities, especially within the US healthcare system.
How might the market respond?
Should Spiro Medical achieve US regulatory clearance, healthcare providers may gain a novel treatment option distinct from pharmaceuticals. This could resonate with segments of the asthma and COPD patient base seeking non-drug interventions. The broader medtech investment community may see this as validation of neuromodulation strategies in respiratory care.
Frequently asked questions
1. What stage is Spiro Medical at?
The company has closed its Series A round, which typically funds technology development and early clinical trials.
2. Who are the lead investors?
Lead investors are Andera Partners, Omega Funds, and Sherpa Healthcare Partners.
3. What will the funding be used for?
Funds are earmarked for product development and US regulatory approval processes.
4. What conditions does the technology address?
Severe asthma, chronic cough, and COPD.
5. Is the treatment drug-based?
No. It uses mild electrical impulses in a neuromodulation system.
Key takeaways
Spiro Medical’s $67 million Series A round signals investor confidence in its approach to respiratory care. By channeling funds into development and regulatory preparation, the company is positioning itself for entry into a highly regulated and competitive US market. For investors and founders, this serves as an example of how international syndicates can support specialized medtech innovation.
Disclaimer
This content is provided for informational purposes only and does not constitute financial advice.